Traditional Naturopath Shares Inspiring Journey to Healing from Addiction, Chronic Illness in Debut Memoir
19 janv. 2021 07h00 HE | Balboa Press
GIBSON, La., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Author and traditional naturopath Michelle L. Potter has published her uplifting memoir that invites readers to share in Potter’s persistence and...
Seven Leading Non-Profit Providers Leverage Experience Treating Patients with Advanced Illness at Home for New, Unique Medicare Care Model
08 déc. 2020 19h12 HE | Capital Caring
Falls Church, Virginia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seven of the nation’s largest and well-known non-profit advanced illness providers have formed Advanced Illness Partners (AIP) to...
Capital Caring Health Partners with Six Leading Non-Profit Providers to Leverage Experience Treating Patients with Advanced Illness at Home
07 déc. 2020 16h59 HE | Capital Caring
Falls Church, Virginia, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Capital Caring Health has joined forces with six of the nation’s largest and well-known non-profit advanced illness providers to form...
Witness a true story of long-term suffering with chronic illness, addiction and Lyme disease transformed by the will to live
10 nov. 2020 01h27 HE | Balboa Press
GIBSON, La., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Despite the debilitating pain, discomfort and mysterious symptoms that Michelle L. Potter had since childhood, doctors kept telling that there is...
NOVARTIS logo.jpg
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
05 juin 2020 01h15 HE | Novartis International AG
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving...
NOVARTIS logo.jpg
Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
16 avr. 2020 01h15 HE | Novartis International AG
Real-world evidence supports benefits seen in Aimovig clinical trials  Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc and...
NOVARTIS logo.jpg
Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
06 janv. 2020 12h05 HE | Novartis International AG
Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL...
NOVARTIS logo.jpg
Novartis completes tender offer for all outstanding shares of The Medicines Company
06 janv. 2020 01h00 HE | Novartis International AG
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger...
Inspire’s Health Profiles Identifies the Insights of Patients to Unlock Research Gaps
13 déc. 2018 08h00 HE | Inspire
ARLINGTON, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Inspire, the leading healthcare social network for patients and caregivers, is offering new opportunities for academic research partners to...
Lyfebulb and UnitedHealth Group Announce Winners of the 2018 Innovation Challenge for Patient Entrepreneurs
26 juil. 2018 09h00 HE | Lyfebulb
MINNETONKA, Minn. and NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- Lyfebulb LLC and UnitedHealth Group (NYSE:UNH) have selected Jon Margalit of Complete Start as the winner of the first-ever Lyfebulb...